Enhancing hemopoietic drug resistance: A rationale for reconsidering the clinical use of mitozolomide

Cancer Gene Therapy

Volumn 7, Issue 2, 2000, Pages 233-239

  Fairbairn, Leslie J ^a,b   Chinnasamy, Nachimuthu ^a   Lashford, Linda S ^b   Chinnasamy, Dhanalakshmi ^a   Rafferty, Joseph A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Alkylating agents; Chemotherapy; Drug resistance; Hemopoiesis; Mitozolomide

Indexed keywords

MITOZOLOMIDE;

ANIMAL CELL; ARTICLE; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROCYTE; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; HEMATOPOIESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

ANIMALIA;

EID: 0034074279     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700120     Document Type: Article

References (48)

1. Prestayko AW. Nitrosoureas: Current Status and New Developments. London: Academic Press; 1981.
2. Witschi H. Responses of the lung to toxic injury. Environ Health Perspect. 1990;85:5-13.
3. O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med. 1990;323:378-382.
4. O'Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA. Late carmustine lung fibrosis: age at treatment may influence severity and survival. Chest. 1995;107:1355-1357.
5. Broggini M, Erba E, Morasca L, Morgan C, D'Incalci M. In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma. Cancer Chemother Pharmacol. 1986;16:125-128.
6. Fodstad O, Aamdal S, Pihl A, Boyd MR. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas. Cancer Res. 1985;45:1778-1786.
7. 3H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res. 1985;45:3008-3013.
8. Newlands ES, Blackledge G, Slack JA, et al. Phase I clinical trial of mitozolomide. Cancer Treat Rep. 1985;69: 801-805.
9. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992;65:287-291.
10. Harding M, Docherty V, Mackie R, Dorward A, Kaye S. Phase II studies of mitozolomide in melanoma, lung, and ovarian cancer. Eur J Cancer Clin Oncol. 1989;25:785-788.
11. Neijt JP, van der Burg ME, Guastalla JP, et al. Phase II trial of mitozolomide in patients with advanced ovarian cancer: a study of the EORTC Gynecological Cancer Cooperative Group. Acta Oncol. 1989;28:663-665.
12. Smyth JF, Gundersen S, Renard J, Pinedo HM. Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group. Eur J Cancer Clin Oncol. 1989;25:755-757.
13. Blackledge G, Roberts JT, Kaye S, et al. A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder. Eur J Cancer Clin Oncol. 1989;25:391-392.
14. Harding M, Northcott D, Smyth J, Stuart NS, Green JA, Newlands E. Phase II evaluation of mitozolomide in ovarian cancer. Br J Cancer. 1988;57:113-114.
15. 6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev. 1988;15:279-292.
16. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990;50: 6119-6129.
17. Margison GP, O'Connor PJ. Biological consequences of reactions with DNA: role of specific lesions. In: Cooper CS, Grover PL, eds. Handbook of Experimental Pharmacology. Berlin: Springer-Verlag; 1990:547-571.
18. 6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Proc Natl Acad Sci USA. 1985;82:2985-2989.
19. 6-methylguanine-DNA methyltransferase. Oncol Res. 1993;5:83-86.
20. 6-benzylguanine plus BCNU. Blood. 1996;88:1649-1655.
21. 6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res. 1992;52:1171-1175.
22. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem Pharmacol. 1993;45:483-491.
23. 6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol. 1993;46:285-290.
24. 6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol. 1993;32: 221-225.
25. 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer. 1996;73:1049-1052.
26. 6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Hematol. 1995;23:112-116.
27. 6-benzylguanine and the 5-fluorouracil/N-(2-chloroethyl)-N-nitrosourea molecular combination, B.4152. Reprod Toxicol. 1996;10:71-77.
28. 6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood. 1997;89:1566-1573.
29. 6-benzylguanine. Cancer Res. 1993;53:4750-4753.
30. 6-benzylguanine. Cancer Res. 1994;54:6221-6227.
31. 6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc Natl Acad Sci USA. 1996;93:14088-14093.
32. 6-alkylguanine-DNA alkyltransferase. Gene Ther. 1996;3:868-877.
33. 6-alkylating agents in vitro. Gene Ther. 1998;5:835-841.
34. 6-alkylguanine-DNA alkyltransferase. Gene Ther. 1998;5:842-847.
35. 6-alkylating agent induced clastogenicity by enhanced DNA repair capacity of bone marrow cells. Mutat Res. 1998;416:1-10.
36. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7:980-982, 984-986, 989-990.
37. Han YM, Yoo OJ, Lee KK. Sex determination in single mouse blastomeres by polymerase chain reaction. J Assist Reprod Genet. 1993;10:151-156.
38. McKeage M, Dady P, Clear M, MacDonald A. A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue. Cancer Chemother Pharmacol. 1992;29:201-206.
39. Ward M, Pioli P, Ayello J, et al. Retroviral transfer and expression of the human multiple drug resistance (MDR) gene in peripheral blood progenitor cells. Clin Cancer Res. 1996;2:873-876.
40. Hanania EG, Deisseroth AB. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther. 1994;1:21-25.
41. Allay JA, Persons DA, Galipeau J, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med. 1998;4:1136-1143.
42. + umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA. Hum Gene Ther. 1998;9:63-71.
43. Momparler R, Eliopoulos N, Bovenzi V, Letourneau S, Grennbaum M, Cournoyer D. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytosine deaminase into murine fibroblasts and hematopoietic cells. Cancer Gene Ther. 1996;3:331-338.
44. Magni M, Shammah S, Schiro R, Mellado W, Dalla Favera R, Gianni AM. Induction of cyclophosphamide resistance by aldehyde-dehydrogenase gene transfer. Blood. 1996;87: 1097-1103.
45. Moreb JS, Schweder M, Gray B, Zucali J, Zori R. In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Hum Gene Ther. 1998;9:611-619.
46. Rafferty JA, Hickson I, Chinnasamy N, et al. Chemoprotection of normal tissues by transfer of drug resistance genes. Cancer Metastasis Rev. 1996;15:365-383.
47. Koc ON, Davis BM, Reese JS, Friebert SE, Gerson SL. Transfer of drug resistance genes into hematopoietic progenitors. In: Lattime EC, Gerson SL, eds. Gene Therapy of Cancer. San Diego: Academic Press; 1998:177-200.
48. 6-methylguanine-induced replication blocks. Carcinogenesis. 1995;16:1775-1782.